위장관 : Helicobacter pylori 에 감염된 소화성 궤양 환자에서 1 주간의 Ranitidine Bismuth Citrate , Amoxicillin , Clarithromycin 삼제요법의 치료 효과

Background/Aims: We performed this study to investigate the efficacy and safety of one-week triple therapy consisted of ranitidine bismuth citrate (RBC), amoxicillin and clarithromycin in the treatment of H. pylori-related peptic ulcers. Methods: Fifty patients with peptic ulcer and H. pylori infection were randomly divided into two groups. One group was administered with RBC 400 mg, amoxicillin 1 g, clarithromycin 500 mg twice daily (RAC group). The other group was administered with or omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg twice daily (OAC group). Four weeks after eradication therapy, H. pylori status, ulcer healing, histological improvement and side effects were assessed. Results: In the RAC group, the eradication rate was 80% (20/25) in the intention-to-treat (ITT) analysis and 95.2% (20/21) in the per protocol (PP) analysis. In the OAC group, the eradication rates in the ITT and PP analysis were 76% (19/25) and 86.4% (19/22), respectively. Ulcer healing rate of the RAC group was 94.7% in the PP analysis. The grade of gastritis was improved after treatment. No significant side effects were noticed in both groups. Conclusions: One-week triple therapy of RBC, amoxicillin, clarithromycin is effective and well tolerated in eradicating H. pylori and healing peptic ulcers. The efficacy is comparable to one-week course of omeprazole-based triple therapy. (Korean J Gastroenterol 2001;37:412-417)